Saturday, July 11, 2026

Drug profile · INN

denosumab-bmwo

denosumab-bmwo (OSENVELT) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — denosumab-bmwo
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

denosumab-bmwo (OSENVELT) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN denosumab-bmwo
Brand OSENVELT
Route INJECTION
Formulation INJECTABLE

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is denosumab-bmwo?

denosumab-bmwo (OSENVELT) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for denosumab-bmwo?

OSENVELT is a marketed brand name for denosumab-bmwo. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of denosumab-bmwo?

denosumab-bmwo has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.